Exact Mass: 700.455

Exact Mass Matches: 700.455

Found 457 metabolites which its exact mass value is equals to given mass value 700.455, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Mycolactone F

Mycolactone F

C42H68O8 (700.4914)


   

PA(18:1(9Z)/18:1(9Z))

[(2R)-2,3-bis[(9Z)-octadec-9-enoyloxy]propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(18:1(9Z)/18:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(9Z)/18:1(9Z)), in particular, consists of one chain of oleic acid at the C-1 position and one chain of oleic acid at the C-2 position. The oleic acid moiety is derived from vegetable oils, especially olive and canola oil, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-CoA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776).

   

PA(18:0/18:2(9Z,12Z))

[(2R)-2-[(9Z,12Z)-octadeca-9,12-dienoyloxy]-3-(octadecanoyloxy)propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(18:0/18:2(9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:0/18:2(9Z,12Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of linoleic acid at the C-2 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil, while the linoleic acid moiety is derived from seed oils. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-coA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776). [HMDB] PA(18:0/18:2(9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:0/18:2(9Z,12Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of linoleic acid at the C-2 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil, while the linoleic acid moiety is derived from seed oils. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-CoA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776).

   

PA(18:1(11Z)/18:1(11Z))

[(2R)-2,3-bis[(11Z)-octadec-11-enoyloxy]propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(18:1(11Z)/18:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(11Z)/18:1(11Z)), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the vaccenic acid moiety is derived from butter fat and animal fat. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-coA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776). [HMDB] PA(18:1(11Z)/18:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(11Z)/18:1(11Z)), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the vaccenic acid moiety is derived from butter fat and animal fat. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-CoA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776).

   

PA(18:1(11Z)/18:1(9Z))

[(2R)-3-[(11Z)-octadec-11-enoyloxy]-2-[(9Z)-octadec-9-enoyloxy]propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(18:1(11Z)/18:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(11Z)/18:1(9Z)), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of oleic acid at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-CoA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776).

   

PA(18:1(9Z)/18:1(11Z))

[(2R)-2-[(11Z)-octadec-11-enoyloxy]-3-[(9Z)-octadec-9-enoyloxy]propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(18:1(9Z)/18:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(9Z)/18:1(11Z)), in particular, consists of one chain of oleic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The oleic acid moiety is derived from vegetable oils, especially olive and canola oil, while the vaccenic acid moiety is derived from butter fat and animal fat. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-CoA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776).

   

9-Octadecenoic acid 1-[(phosphonoxy)methyl]-1,2-ethanediyl ester

[2-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-9-enoate

C39H73O8P (700.5043)


9-Octadecenoic acid 1-[(phosphonoxy)methyl]-1,2-ethanediyl ester is classified as a Natural Food Constituent (code WA) in the DF Classified as a Natural Food Constituent (code WA) in the DFC

   

PA(14:1(9Z)/22:1(13Z))

[(2R)-2-[(13Z)-docos-13-enoyloxy]-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(14:1(9Z)/22:1(13Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(14:1(9Z)/22:1(13Z)), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of erucic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(18:2(9Z,12Z)/18:0)

[(2R)-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]-2-(octadecanoyloxy)propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(18:2(9Z,12Z)/18:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:2(9Z,12Z)/18:0), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of stearic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(20:1(11Z)/16:1(9Z))

[(2R)-2-[(9Z)-hexadec-9-enoyloxy]-3-[(11Z)-icos-11-enoyloxy]propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(20:1(11Z)/16:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:1(11Z)/16:1(9Z)), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(22:1(13Z)/14:1(9Z))

[(2R)-3-[(13Z)-docos-13-enoyloxy]-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(22:1(13Z)/14:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:1(13Z)/14:1(9Z)), in particular, consists of one chain of erucic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(22:2(13Z,16Z)/14:0)

[(2R)-3-[(13Z,16Z)-docosa-13,16-dienoyloxy]-2-(tetradecanoyloxy)propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(22:2(13Z,16Z)/14:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:2(13Z,16Z)/14:0), in particular, consists of one chain of docosadienoic acid at the C-1 position and one chain of myristic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(16:0/20:2(11Z,14Z))

[(2R)-3-(hexadecanoyloxy)-2-[(11Z,14Z)-icosa-11,14-dienoyloxy]propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(16:0/20:2(11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:0/20:2(11Z,14Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of eicosadienoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(20:2(11Z,14Z)/16:0)

[(2R)-2-(hexadecanoyloxy)-3-[(11Z,14Z)-icosa-11,14-dienoyloxy]propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(20:2(11Z,14Z)/16:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:2(11Z,14Z)/16:0), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of palmitic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(14:0/22:2(13Z,16Z))

[(2R)-2-[(13Z,16Z)-docosa-13,16-dienoyloxy]-3-(tetradecanoyloxy)propoxy]phosphonic acid

C39H73O8P (700.5043)


PA(14:0/22:2(13Z,16Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(14:0/22:2(13Z,16Z)), in particular, consists of one tetradecanoyl chain to the C-1 atom, and one 13Z,16Z-docosadienoyl to the C-2 atom. The oleic acid moiety is derived from vegetable oils, especially olive and canola oil, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

[(2R)-2-{[(5R,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/14:0)

[(2R)-3-{[(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/14:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

[(2R)-2-{[(5S,6E,8Z,11Z,13E,15R)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/14:0)

[(2R)-3-{[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/14:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

[(2R)-2-{[(5R,6R,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/14:0)

[(2R)-3-{[(5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/14:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(14:1(9Z)/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:1(9Z))

[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:1(9Z)), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(15:0/20:3(6,8,11)-OH(5))

[(2R)-2-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-3-(pentadecanoyloxy)propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(15:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(15:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one pentadecanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(6,8,11)-OH(5)/15:0)

[(2R)-3-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-2-(pentadecanoyloxy)propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(20:3(6,8,11)-OH(5)/15:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(6,8,11)-OH(5)/15:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of pentadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(17:0/18:2(10E,12Z)+=O(9))

[(2R)-3-(heptadecanoyloxy)-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(17:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(17:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one heptadecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(10E,12Z)+=O(9)/17:0)

[(2R)-2-(heptadecanoyloxy)-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:2(10E,12Z)+=O(9)/17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/17:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of heptadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(17:0/18:2(9Z,11E)+=O(13))

[(2R)-3-(heptadecanoyloxy)-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(17:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(17:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one heptadecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(9Z,11E)+=O(13)/17:0)

[(2R)-2-(heptadecanoyloxy)-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:2(9Z,11E)+=O(13)/17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/17:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of heptadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(17:0/18:3(10,12,15)-OH(9))

[(2R)-3-(heptadecanoyloxy)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(17:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(17:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one heptadecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(10,12,15)-OH(9)/17:0)

[(2R)-2-(heptadecanoyloxy)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:3(10,12,15)-OH(9)/17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/17:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of heptadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(17:0/18:3(9,11,15)-OH(13))

[(2R)-3-(heptadecanoyloxy)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(17:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(17:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one heptadecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9,11,15)-OH(13)/17:0)

[(2R)-2-(heptadecanoyloxy)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:3(9,11,15)-OH(13)/17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/17:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of heptadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-15:0/20:3(6,8,11)-OH(5))

[(2R)-2-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-3-[(12-methyltetradecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(a-15:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-15:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one 12-methyltetradecanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(6,8,11)-OH(5)/a-15:0)

[(2R)-3-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-2-[(12-methyltetradecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(20:3(6,8,11)-OH(5)/a-15:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(6,8,11)-OH(5)/a-15:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of 12-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-17:0/18:2(10E,12Z)+=O(9))

[(2R)-3-[(14-methylhexadecanoyl)oxy]-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(a-17:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-17:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(10E,12Z)+=O(9)/a-17:0)

[(2R)-2-[(14-methylhexadecanoyl)oxy]-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:2(10E,12Z)+=O(9)/a-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/a-17:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-17:0/18:2(9Z,11E)+=O(13))

[(2R)-3-[(14-methylhexadecanoyl)oxy]-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(a-17:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-17:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(9Z,11E)+=O(13)/a-17:0)

[(2R)-2-[(14-methylhexadecanoyl)oxy]-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:2(9Z,11E)+=O(13)/a-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/a-17:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-17:0/18:3(10,12,15)-OH(9))

[(2R)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-3-[(14-methylhexadecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(a-17:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-17:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(10,12,15)-OH(9)/a-17:0)

[(2R)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-2-[(14-methylhexadecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:3(10,12,15)-OH(9)/a-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/a-17:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-17:0/18:3(9,11,15)-OH(13))

[(2R)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-3-[(14-methylhexadecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(a-17:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-17:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9,11,15)-OH(13)/a-17:0)

[(2R)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-2-[(14-methylhexadecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:3(9,11,15)-OH(13)/a-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/a-17:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

[(2R)-2-{[(5R,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(i-14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-14:0)

[(2R)-3-{[(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-14:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

[(2R)-2-{[(5S,6E,8Z,11Z,13E,15R)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(i-14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-14:0)

[(2R)-3-{[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-14:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

[(2R)-2-{[(5R,6R,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(i-14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-14:0)

[(2R)-3-{[(5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O10P (700.4315)


PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-14:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-15:0/20:3(6,8,11)-OH(5))

[(2R)-2-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-3-[(13-methyltetradecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(i-15:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-15:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one 13-methyltetradecanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(6,8,11)-OH(5)/i-15:0)

[(2R)-3-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-2-[(13-methyltetradecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(20:3(6,8,11)-OH(5)/i-15:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(6,8,11)-OH(5)/i-15:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of 13-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-17:0/18:2(10E,12Z)+=O(9))

[(2R)-3-[(15-methylhexadecanoyl)oxy]-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(i-17:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-17:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(10E,12Z)+=O(9)/i-17:0)

[(2R)-2-[(15-methylhexadecanoyl)oxy]-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:2(10E,12Z)+=O(9)/i-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/i-17:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-17:0/18:2(9Z,11E)+=O(13))

[(2R)-3-[(15-methylhexadecanoyl)oxy]-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(i-17:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-17:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(9Z,11E)+=O(13)/i-17:0)

[(2R)-2-[(15-methylhexadecanoyl)oxy]-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:2(9Z,11E)+=O(13)/i-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/i-17:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-17:0/18:3(10,12,15)-OH(9))

[(2R)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-3-[(15-methylhexadecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(i-17:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-17:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(10,12,15)-OH(9)/i-17:0)

[(2R)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-2-[(15-methylhexadecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:3(10,12,15)-OH(9)/i-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/i-17:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-17:0/18:3(9,11,15)-OH(13))

[(2R)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-3-[(15-methylhexadecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(i-17:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-17:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9,11,15)-OH(13)/i-17:0)

[(2R)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-2-[(15-methylhexadecanoyl)oxy]propoxy]phosphonic acid

C38H69O9P (700.4679)


PA(18:3(9,11,15)-OH(13)/i-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/i-17:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

14-Acetoxy-22,23-dihydro-15,23-dihydroxyirpexan

14-Acetoxy-22,23-dihydro-15,23-dihydroxyirpexan

C38H68O11 (700.4761)


   

Antibiotic MK 2266A

Antibiotic MK 2266A

C41H64O9 (700.455)


   

Antibiotic MK 2266

Antibiotic MK 2266

C41H64O9 (700.455)


   

Desacetylnyalolide

Desacetylnyalolide

C41H64O9 (700.455)


   

Inostamycin B

(2S,4S,5R)-20-De(1-hydroxypropyl)-6-demethyl-6-ethyl-5-hydroxy-20-(1-hydroxypentyl)-2-methyl-lysocellin

C38H68O11 (700.4761)


   

Fcoxanthin acetate

Fcoxanthin acetate

C44H60O7 (700.4339)


   

lobophytone K

lobophytone K

C41H64O9 (700.455)


   
   

Milbemycin alpha-8

Milbemycin alpha-8

C40H60O10 (700.4186)


   
   

lobophytone C

lobophytone C

C41H64O9 (700.455)


   

lobophytone U

lobophytone U

C41H64O9 (700.455)


   

methyl (1E,5S,6R,9R,10S,12S,14aR,17S,20R,24S,26aS,26bR)-4,5,6,7,8,9,10,11,12,14,15,16,17,18,19,20,21,22,23,24,25,26,26a,26b-tetracosahydro-5,6,10-trihydroxy-2,6,10,13,20,24-hexamethyl-16,19,26-trioxo-17-(propan-2-yl)-9,12-epoxybenzo[1,2-a:3,4-a?]di[14]annulene-14a(3H)-carboxylate|sarcophytolide G

methyl (1E,5S,6R,9R,10S,12S,14aR,17S,20R,24S,26aS,26bR)-4,5,6,7,8,9,10,11,12,14,15,16,17,18,19,20,21,22,23,24,25,26,26a,26b-tetracosahydro-5,6,10-trihydroxy-2,6,10,13,20,24-hexamethyl-16,19,26-trioxo-17-(propan-2-yl)-9,12-epoxybenzo[1,2-a:3,4-a?]di[14]annulene-14a(3H)-carboxylate|sarcophytolide G

C41H64O9 (700.455)


   

sinulaflexiolide A

sinulaflexiolide A

C41H64O9 (700.455)


   

3-propanoylonchidionol

3-propanoylonchidionol

C40H60O10 (700.4186)


   

3alpha,29-O-di-trans-cinnamoyl-D:C-friedooleana-7,9(11)-diene

3alpha,29-O-di-trans-cinnamoyl-D:C-friedooleana-7,9(11)-diene

C48H60O4 (700.4491)


   

C40H60O10_1-Naphthalenebutanoic acid, decahydro-beta,6-dihydroxy-alpha-(2-hydroxyethylidene)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-, (4E)-4-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]tetrahydro-5-oxo-3-furanyl ester, (alphaE,1R,4aS,5R,6R,8aS)

NCGC00381206-01_C40H60O10_1-Naphthalenebutanoic acid, decahydro-beta,6-dihydroxy-alpha-(2-hydroxyethylidene)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-, (4E)-4-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]tetrahydro-5-oxo-3-furanyl ester, (alphaE,1R,4aS,5R,6R,8aS)-

C40H60O10 (700.4186)


   

Thermoactinoamide_B

Thermoactinoamide_B

C37H60N6O7 (700.4523)


   

RLREK

Arg-Leu-Arg-Glu-Lys

C29H56N12O8 (700.4344)


   

1,2-Dioleoyl-sn-glycero-3-phosphate

1,2-Dioleoyl-sn-glycero-3-phosphate

C39H73O8P (700.5043)


   

Dioleoyl phosphatidic acid

9-Octadecenoic acid (Z)-, 1-[(phosphonooxy)methyl]-1,2-ethanediyl ester

C39H73O8P (700.5043)


A phosphatidic acid in which the phosphatidyl acyl groups are both oleoyl.

   

PA(18:0/18:2)

1-octadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate

C39H73O8P (700.5043)


   

Dioleoylphosphatidic acid

Dioleoylphosphatidic acid

C39H73O8P (700.5043)


   

PA(36:2)

1-(9Z-octadecenoyl)-2-(11Z-octadecenoyl)-sn-phosphatidic acid

C39H73O8P (700.5043)


   

PG(13:0/18:4(6Z,9Z,12Z,15Z))

1-tridecanoyl-2-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-glycero-3-phospho-(1-sn-glycerol)

C37H65O10P (700.4315)


   

PG(18:4(6Z,9Z,12Z,15Z)/13:0)

1-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-2-tridecanoyl-glycero-3-phospho-(1-sn-glycerol)

C37H65O10P (700.4315)


   

PA(14:0/22:2(13Z,16Z))

1-tetradecanoyl-2-(13Z,16Z-docosadienoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(14:1(9Z)/22:1(11Z))

1-(9Z-tetradecenoyl)-2-(11Z-docosenoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(16:0/20:2(11Z,14Z))

1-hexadecanoyl-2-(11Z,14Z-eicosadienoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(16:1(9Z)/20:1(11Z))

1-(9Z-hexadecenoyl)-2-(11Z-eicosenoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(17:1(9Z)/19:1(9Z))

1-(9Z-heptadecenoyl)-2-(9Z-nonadecenoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(17:2(9Z,12Z)/19:0)

1-(9Z,12Z-heptadecadienoyl)-2-nonadecanoyl-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(19:0/17:2(9Z,12Z))

1-nonadecanoyl-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(19:1(9Z)/17:1(9Z))

1-(9Z-nonadecenoyl)-2-(9Z-heptadecenoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(20:1(11Z)/16:1(9Z))

1-(11Z-eicosenoyl)-2-(9Z-hexadecenoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(20:2(11Z,14Z)/16:0)

1-(11Z,14Z-eicosadienoyl)-2-hexadecanoyl-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(22:1(11Z)/14:1(9Z))

1-(11Z-docosenoyl)-2-(9Z-tetradecenoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(22:2(13Z,16Z)/14:0)

1-(13Z,16Z-docosadienoyl)-2-tetradecanoyl-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(18:2(9Z,12Z)/18:0)

1-(9Z,12Z-octadecadienoyl)-2-octadecanoyl-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(18:1(9Z)/18:1(9Z))

1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate

C39H73O8P (700.5043)


   

PG 31:4

1-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-2-tridecanoyl-glycero-3-phospho-(1-sn-glycerol)

C37H65O10P (700.4315)


   

PA 36:2

1-octadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate

C39H73O8P (700.5043)


   

PEth 34:2

1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanol

C39H73O8P (700.5043)


   

Fuscaside B

(24S)-3,24-di-O-(beta-D-xylopyranosyl)-5alpha-cholestane-3beta,6beta,8,15alpha,24-pentol

C37H64O12 (700.4398)


   

Fucoxanthin 3-acetate

(3S,5R,6S,3S,5R,6R)-5,6-Epoxy-3,3-diethanoyloxy-5-hydroxy-6,7-didehydro-5,6,7,8,5,6-hexahydro-beta,beta-caroten-8-one

C44H60O7 (700.4339)


   

Bis(tetrabutylammonium) Dichromate

Bis(tetrabutylammonium) Dichromate

C32H72Cr2N2O7 (700.4149)


   

magnesium ionophore vii

magnesium ionophore vii

C38H60N4O8 (700.4411)


   

3-(Phosphonooxy)propane-1,2-diyl dioctadec-9-enoate

3-(Phosphonooxy)propane-1,2-diyl dioctadec-9-enoate

C39H73O8P (700.5043)


   

1-Stearoyl-2-oleoyl-sn-glycero-3-phosphate(2-)

1-Stearoyl-2-oleoyl-sn-glycero-3-phosphate(2-)

C39H73O8P-2 (700.5043)


   

[(2R)-2-[(E)-octadec-8-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-8-enoate

[(2R)-2-[(E)-octadec-8-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-8-enoate

C39H73O8P (700.5043)


   

PA(17:0/18:2(10E,12Z)+=O(9))

PA(17:0/18:2(10E,12Z)+=O(9))

C38H69O9P (700.4679)


   

PA(18:2(10E,12Z)+=O(9)/17:0)

PA(18:2(10E,12Z)+=O(9)/17:0)

C38H69O9P (700.4679)


   

PA(17:0/18:2(9Z,11E)+=O(13))

PA(17:0/18:2(9Z,11E)+=O(13))

C38H69O9P (700.4679)


   

PA(18:2(9Z,11E)+=O(13)/17:0)

PA(18:2(9Z,11E)+=O(13)/17:0)

C38H69O9P (700.4679)


   

PA(a-15:0/20:3(6,8,11)-OH(5))

PA(a-15:0/20:3(6,8,11)-OH(5))

C38H69O9P (700.4679)


   

PA(20:3(6,8,11)-OH(5)/a-15:0)

PA(20:3(6,8,11)-OH(5)/a-15:0)

C38H69O9P (700.4679)


   

PA(a-17:0/18:2(10E,12Z)+=O(9))

PA(a-17:0/18:2(10E,12Z)+=O(9))

C38H69O9P (700.4679)


   

PA(18:2(10E,12Z)+=O(9)/a-17:0)

PA(18:2(10E,12Z)+=O(9)/a-17:0)

C38H69O9P (700.4679)


   

PA(a-17:0/18:2(9Z,11E)+=O(13))

PA(a-17:0/18:2(9Z,11E)+=O(13))

C38H69O9P (700.4679)


   

PA(18:2(9Z,11E)+=O(13)/a-17:0)

PA(18:2(9Z,11E)+=O(13)/a-17:0)

C38H69O9P (700.4679)


   

PA(i-15:0/20:3(6,8,11)-OH(5))

PA(i-15:0/20:3(6,8,11)-OH(5))

C38H69O9P (700.4679)


   

PA(20:3(6,8,11)-OH(5)/i-15:0)

PA(20:3(6,8,11)-OH(5)/i-15:0)

C38H69O9P (700.4679)


   

PA(i-17:0/18:2(10E,12Z)+=O(9))

PA(i-17:0/18:2(10E,12Z)+=O(9))

C38H69O9P (700.4679)


   

PA(18:2(10E,12Z)+=O(9)/i-17:0)

PA(18:2(10E,12Z)+=O(9)/i-17:0)

C38H69O9P (700.4679)


   

PA(i-17:0/18:2(9Z,11E)+=O(13))

PA(i-17:0/18:2(9Z,11E)+=O(13))

C38H69O9P (700.4679)


   

PA(18:2(9Z,11E)+=O(13)/i-17:0)

PA(18:2(9Z,11E)+=O(13)/i-17:0)

C38H69O9P (700.4679)


   

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C38H69O9P (700.4679)


   

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C38H69O9P (700.4679)


   

[(2R)-1-heptadecanoyloxy-3-phosphonooxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

[(2R)-1-heptadecanoyloxy-3-phosphonooxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C38H69O9P (700.4679)


   

[(2R)-2-heptadecanoyloxy-3-phosphonooxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

[(2R)-2-heptadecanoyloxy-3-phosphonooxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C38H69O9P (700.4679)


   

[(2R)-1-heptadecanoyloxy-3-phosphonooxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

[(2R)-1-heptadecanoyloxy-3-phosphonooxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C38H69O9P (700.4679)


   

[(2R)-2-heptadecanoyloxy-3-phosphonooxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

[(2R)-2-heptadecanoyloxy-3-phosphonooxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C38H69O9P (700.4679)


   

PA(a-17:0/18:3(10,12,15)-OH(9))

PA(a-17:0/18:3(10,12,15)-OH(9))

C38H69O9P (700.4679)


   

PA(18:3(10,12,15)-OH(9)/a-17:0)

PA(18:3(10,12,15)-OH(9)/a-17:0)

C38H69O9P (700.4679)


   

PA(a-17:0/18:3(9,11,15)-OH(13))

PA(a-17:0/18:3(9,11,15)-OH(13))

C38H69O9P (700.4679)


   

PA(18:3(9,11,15)-OH(13)/a-17:0)

PA(18:3(9,11,15)-OH(13)/a-17:0)

C38H69O9P (700.4679)


   

PA(i-17:0/18:3(10,12,15)-OH(9))

PA(i-17:0/18:3(10,12,15)-OH(9))

C38H69O9P (700.4679)


   

PA(18:3(10,12,15)-OH(9)/i-17:0)

PA(18:3(10,12,15)-OH(9)/i-17:0)

C38H69O9P (700.4679)


   

PA(i-17:0/18:3(9,11,15)-OH(13))

PA(i-17:0/18:3(9,11,15)-OH(13))

C38H69O9P (700.4679)


   

PA(18:3(9,11,15)-OH(13)/i-17:0)

PA(18:3(9,11,15)-OH(13)/i-17:0)

C38H69O9P (700.4679)


   

PA(14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

PA(14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C37H65O10P (700.4315)


   

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/14:0)

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/14:0)

C37H65O10P (700.4315)


   

PA(14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

PA(14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C37H65O10P (700.4315)


   

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/14:0)

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/14:0)

C37H65O10P (700.4315)


   

PA(14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

PA(14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C37H65O10P (700.4315)


   

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/14:0)

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/14:0)

C37H65O10P (700.4315)


   

PA(14:1(9Z)/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(14:1(9Z)/20:3(8Z,11Z,14Z)-2OH(5,6))

C37H65O10P (700.4315)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:1(9Z))

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:1(9Z))

C37H65O10P (700.4315)


   

PA(i-14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

PA(i-14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C37H65O10P (700.4315)


   

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-14:0)

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-14:0)

C37H65O10P (700.4315)


   

PA(i-14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

PA(i-14:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C37H65O10P (700.4315)


   

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-14:0)

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-14:0)

C37H65O10P (700.4315)


   

PA(i-14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

PA(i-14:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C37H65O10P (700.4315)


   

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-14:0)

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-14:0)

C37H65O10P (700.4315)


   

Bionectriol D

Bionectriol D

C38H68O11 (700.4761)


   

1-Oleoyl-2-stearoyl-sn-glycero-3-phosphate(2-)

1-Oleoyl-2-stearoyl-sn-glycero-3-phosphate(2-)

C39H73O8P-2 (700.5043)


   

1-oleoyl-2-(6Z)-octadecenoyl-sn-glycero-3-phosphate

1-oleoyl-2-(6Z)-octadecenoyl-sn-glycero-3-phosphate

C39H73O8P (700.5043)


A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as oleoyl and (6Z)-octadecenoyl respectively.

   

Lobophytone A

Lobophytone A

C41H64O9 (700.455)


   

PEtOH 16:0_18:2

PEtOH 16:0_18:2

C39H73O8P (700.5043)


   

NAGlySer 16:4/20:1

NAGlySer 16:4/20:1

C41H68N2O7 (700.5026)


   

NAGlySer 18:3/18:2

NAGlySer 18:3/18:2

C41H68N2O7 (700.5026)


   

NAGlySer 22:5/14:0

NAGlySer 22:5/14:0

C41H68N2O7 (700.5026)


   

NAGlySer 20:2/16:3

NAGlySer 20:2/16:3

C41H68N2O7 (700.5026)


   

NAGlySer 24:5/12:0

NAGlySer 24:5/12:0

C41H68N2O7 (700.5026)


   

NAGlySer 18:5/18:0

NAGlySer 18:5/18:0

C41H68N2O7 (700.5026)


   

NAGlySer 18:2/18:3

NAGlySer 18:2/18:3

C41H68N2O7 (700.5026)


   

NAGlySer 16:3/20:2

NAGlySer 16:3/20:2

C41H68N2O7 (700.5026)


   

NAGlySer 20:4/16:1

NAGlySer 20:4/16:1

C41H68N2O7 (700.5026)


   

NAGlySer 16:1/20:4

NAGlySer 16:1/20:4

C41H68N2O7 (700.5026)


   

NAGlySer 22:4/14:1

NAGlySer 22:4/14:1

C41H68N2O7 (700.5026)


   

NAGlySer 20:3/16:2

NAGlySer 20:3/16:2

C41H68N2O7 (700.5026)


   

NAGlySer 26:5/10:0

NAGlySer 26:5/10:0

C41H68N2O7 (700.5026)


   

NAGlySer 16:2/20:3

NAGlySer 16:2/20:3

C41H68N2O7 (700.5026)


   

NAGlySer 14:0/22:5

NAGlySer 14:0/22:5

C41H68N2O7 (700.5026)


   

NAGlySer 18:4/18:1

NAGlySer 18:4/18:1

C41H68N2O7 (700.5026)


   

NAGlySer 20:5/16:0

NAGlySer 20:5/16:0

C41H68N2O7 (700.5026)


   

NAGlySer 14:1/22:4

NAGlySer 14:1/22:4

C41H68N2O7 (700.5026)


   

Mgdg O-16:4_16:4

Mgdg O-16:4_16:4

C41H64O9 (700.455)


   

PE-Cer 14:3;2O/24:6

PE-Cer 14:3;2O/24:6

C40H65N2O6P (700.458)


   

PE-Cer 16:3;2O/22:6

PE-Cer 16:3;2O/22:6

C40H65N2O6P (700.458)


   

PE-Cer 12:2;2O/26:7

PE-Cer 12:2;2O/26:7

C40H65N2O6P (700.458)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C38H69O9P (700.4679)


   

[1-decoxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-decoxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] decanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] decanoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (Z)-tetradec-9-enoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (Z)-tetradec-9-enoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] dodecanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] dodecanoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] hexadecanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] hexadecanoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (Z)-hexadec-9-enoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (Z)-hexadec-9-enoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C38H69O9P (700.4679)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] tetradecanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] tetradecanoate

C38H69O9P (700.4679)


   

PMeOH 16:1_19:1

PMeOH 16:1_19:1

C39H73O8P (700.5043)


   

PEtOH 12:0_22:2

PEtOH 12:0_22:2

C39H73O8P (700.5043)


   

PEtOH 14:1_20:1

PEtOH 14:1_20:1

C39H73O8P (700.5043)


   

PMeOH 16:4_20:5

PMeOH 16:4_20:5

C40H61O8P (700.4104)


   

PEtOH 17:0_17:2

PEtOH 17:0_17:2

C39H73O8P (700.5043)


   

PEtOH 18:0_16:2

PEtOH 18:0_16:2

C39H73O8P (700.5043)


   

PMeOH 18:0_17:2

PMeOH 18:0_17:2

C39H73O8P (700.5043)


   

PEtOH 15:1_19:1

PEtOH 15:1_19:1

C39H73O8P (700.5043)


   

PMeOH 19:0_16:2

PMeOH 19:0_16:2

C39H73O8P (700.5043)


   

PMeOH 13:1_22:1

PMeOH 13:1_22:1

C39H73O8P (700.5043)


   

PEtOH 17:1_17:1

PEtOH 17:1_17:1

C39H73O8P (700.5043)


   

PEtOH 15:0_19:2

PEtOH 15:0_19:2

C39H73O8P (700.5043)


   

PMeOH 18:4_18:5

PMeOH 18:4_18:5

C40H61O8P (700.4104)


   

PMeOH 13:0_22:2

PMeOH 13:0_22:2

C39H73O8P (700.5043)


   

PEtOH 14:0_20:2

PEtOH 14:0_20:2

C39H73O8P (700.5043)


   

PMeOH 15:1_20:1

PMeOH 15:1_20:1

C39H73O8P (700.5043)


   

PEtOH 13:0_21:2

PEtOH 13:0_21:2

C39H73O8P (700.5043)


   

PMeOH 14:1_21:1

PMeOH 14:1_21:1

C39H73O8P (700.5043)


   

PMeOH 17:0_18:2

PMeOH 17:0_18:2

C39H73O8P (700.5043)


   

PMeOH 14:0_21:2

PMeOH 14:0_21:2

C39H73O8P (700.5043)


   

PEtOH 16:1_18:1

PEtOH 16:1_18:1

C39H73O8P (700.5043)


   

PMeOH 15:0_20:2

PMeOH 15:0_20:2

C39H73O8P (700.5043)


   

PMeOH 17:1_18:1

PMeOH 17:1_18:1

C39H73O8P (700.5043)


   

PEtOH 13:1_21:1

PEtOH 13:1_21:1

C39H73O8P (700.5043)


   

PMeOH 16:0_19:2

PMeOH 16:0_19:2

C39H73O8P (700.5043)


   

6-[2-hexadecanoyloxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

6-[2-hexadecanoyloxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C38H68O11 (700.4761)


   

6-[3-[(Z)-hexadec-9-enoyl]oxy-2-tridecanoyloxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

6-[3-[(Z)-hexadec-9-enoyl]oxy-2-tridecanoyloxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C38H68O11 (700.4761)


   

3,4,5-trihydroxy-6-[2-pentadecanoyloxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]oxane-2-carboxylic acid

3,4,5-trihydroxy-6-[2-pentadecanoyloxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]oxane-2-carboxylic acid

C38H68O11 (700.4761)


   

3,4,5-trihydroxy-6-[3-[(Z)-pentadec-9-enoyl]oxy-2-tetradecanoyloxypropoxy]oxane-2-carboxylic acid

3,4,5-trihydroxy-6-[3-[(Z)-pentadec-9-enoyl]oxy-2-tetradecanoyloxypropoxy]oxane-2-carboxylic acid

C38H68O11 (700.4761)


   

6-[2-dodecanoyloxy-3-[(Z)-heptadec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

6-[2-dodecanoyloxy-3-[(Z)-heptadec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C38H68O11 (700.4761)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C37H65O10P (700.4315)


   

[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C37H65O10P (700.4315)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

C37H65O10P (700.4315)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentadecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentadecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C37H65O10P (700.4315)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C37H65O10P (700.4315)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C37H65O10P (700.4315)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tridecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tridecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C37H65O10P (700.4315)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C37H65O10P (700.4315)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C37H65O10P (700.4315)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

C37H65O10P (700.4315)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C37H65O10P (700.4315)


   

[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

C39H73O8P (700.5043)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C37H65O10P (700.4315)


   

(1-dodecanoyloxy-3-phosphonooxypropan-2-yl) (13Z,16Z)-tetracosa-13,16-dienoate

(1-dodecanoyloxy-3-phosphonooxypropan-2-yl) (13Z,16Z)-tetracosa-13,16-dienoate

C39H73O8P (700.5043)


   

(1-heptadecanoyloxy-3-phosphonooxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate

(1-heptadecanoyloxy-3-phosphonooxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate

C39H73O8P (700.5043)


   

(1-phosphonooxy-3-tetradecanoyloxypropan-2-yl) (13Z,16Z)-docosa-13,16-dienoate

(1-phosphonooxy-3-tetradecanoyloxypropan-2-yl) (13Z,16Z)-docosa-13,16-dienoate

C39H73O8P (700.5043)


   

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (11Z,14Z)-henicosa-11,14-dienoate

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (11Z,14Z)-henicosa-11,14-dienoate

C39H73O8P (700.5043)


   

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (Z)-henicos-11-enoate

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (Z)-henicos-11-enoate

C39H73O8P (700.5043)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C37H65O10P (700.4315)


   

(1-hexadecanoyloxy-3-phosphonooxypropan-2-yl) (11Z,14Z)-icosa-11,14-dienoate

(1-hexadecanoyloxy-3-phosphonooxypropan-2-yl) (11Z,14Z)-icosa-11,14-dienoate

C39H73O8P (700.5043)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C37H65O10P (700.4315)


   

[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] icosanoate

[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] icosanoate

C39H73O8P (700.5043)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C37H65O10P (700.4315)


   

[1-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (Z)-icos-11-enoate

[1-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (Z)-icos-11-enoate

C39H73O8P (700.5043)


   

[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] nonadecanoate

[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] nonadecanoate

C39H73O8P (700.5043)


   

(1-decanoyloxy-3-phosphonooxypropan-2-yl) (15Z,18Z)-hexacosa-15,18-dienoate

(1-decanoyloxy-3-phosphonooxypropan-2-yl) (15Z,18Z)-hexacosa-15,18-dienoate

C39H73O8P (700.5043)


   

[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (Z)-docos-13-enoate

[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (Z)-docos-13-enoate

C39H73O8P (700.5043)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C37H65O10P (700.4315)


   

[1-[(Z)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (Z)-nonadec-9-enoate

[1-[(Z)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (Z)-nonadec-9-enoate

C39H73O8P (700.5043)


   

[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(5Z,8Z,11Z)-tetradeca-5,8,11-trienoyl]oxypropyl] (5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoate

[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(5Z,8Z,11Z)-tetradeca-5,8,11-trienoyl]oxypropyl] (5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoate

C45H64O6 (700.4703)


   

2,3-bis[[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy]propyl (7Z,9Z,11Z,13Z,15Z)-octadeca-7,9,11,13,15-pentaenoate

2,3-bis[[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy]propyl (7Z,9Z,11Z,13Z,15Z)-octadeca-7,9,11,13,15-pentaenoate

C45H64O6 (700.4703)


   

[1-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C40H60O10 (700.4186)


   

[1-O,2-O-Bis[(E)-9-octadecenoyl]-L-glycerol-3-O-yl]phosphonic acid

[1-O,2-O-Bis[(E)-9-octadecenoyl]-L-glycerol-3-O-yl]phosphonic acid

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-11-enoate

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-11-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

[(2R)-2-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

C39H73O8P (700.5043)


   

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (13E,16E)-docosa-13,16-dienoate

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (13E,16E)-docosa-13,16-dienoate

C39H73O8P (700.5043)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C37H65O10P (700.4315)


   

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tridecanoyloxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tridecanoyloxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C37H65O10P (700.4315)


   

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C37H65O10P (700.4315)


   

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

[(2R)-1-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate

[(2R)-1-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-7-enoate

[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-7-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-9-enoate

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-9-enoate

C39H73O8P (700.5043)


   

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

2-[[(2R)-3-dodecanoyloxy-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-dodecanoyloxy-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] nonadecanoate

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] nonadecanoate

C39H73O8P (700.5043)


   

[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (5E,9E)-hexacosa-5,9-dienoate

[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (5E,9E)-hexacosa-5,9-dienoate

C39H73O8P (700.5043)


   

[(2R)-2-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

[(2R)-2-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

C39H73O8P (700.5043)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C37H65O10P (700.4315)


   

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-13-enoate

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-13-enoate

C39H73O8P (700.5043)


   

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-13-enoate

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-13-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-9-enoate

[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-9-enoate

C39H73O8P (700.5043)


   

2-[[(2S)-2-dodecanoyloxy-3-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2S)-2-dodecanoyloxy-3-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-9-enoate

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-9-enoate

C39H73O8P (700.5043)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C37H65O10P (700.4315)


   

[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate

[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate

C39H73O8P (700.5043)


   

2-[[(2R)-3-decanoyloxy-2-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-decanoyloxy-2-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-9-enoate

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-9-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C37H65O10P (700.4315)


   

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

C39H73O8P (700.5043)


   

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-9-enoate

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-9-enoate

C39H73O8P (700.5043)


   

2-[[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-tetradecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-tetradecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-icos-13-enoate

[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-icos-13-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-11-enoate

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-11-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-icos-11-enoate

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-icos-11-enoate

C39H73O8P (700.5043)


   

2-[[(2S)-2-decanoyloxy-3-[(8E,11E,14E)-icosa-8,11,14-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2S)-2-decanoyloxy-3-[(8E,11E,14E)-icosa-8,11,14-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[(2R)-1-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate

[(2R)-1-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-11-enoate

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-11-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

C39H73O8P (700.5043)


   

2-[[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (11E,14E)-icosa-11,14-dienoate

[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (11E,14E)-icosa-11,14-dienoate

C39H73O8P (700.5043)


   

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

[(2R)-1-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-docos-13-enoate

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-docos-13-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-4-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

[(2R)-2-[(E)-octadec-4-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-13-enoate

[(2R)-1-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-13-enoate

C39H73O8P (700.5043)


   

[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (5E,8E)-icosa-5,8-dienoate

[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (5E,8E)-icosa-5,8-dienoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-icos-13-enoate

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-icos-13-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

[(2R)-2-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C37H65O10P (700.4315)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoate

C40H61O8P (700.4104)


   

[(2R)-1-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-13-enoate

[(2R)-1-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-13-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

2-[[(2R)-3-dodecanoyloxy-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-dodecanoyloxy-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (5E,9E)-hexacosa-5,9-dienoate

[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (5E,9E)-hexacosa-5,9-dienoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-11-enoate

[(2R)-1-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-11-enoate

C39H73O8P (700.5043)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C37H65O10P (700.4315)


   

[(2R)-2-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

[(2R)-2-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

C39H73O8P (700.5043)


   

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] nonadecanoate

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] nonadecanoate

C39H73O8P (700.5043)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tridecanoyloxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tridecanoyloxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C37H65O10P (700.4315)


   

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-7-enoate

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-7-enoate

C39H73O8P (700.5043)


   

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C37H65O10P (700.4315)


   

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

2-[[(2R)-3-decanoyloxy-2-[(8E,11E,14E)-icosa-8,11,14-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-decanoyloxy-2-[(8E,11E,14E)-icosa-8,11,14-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoate

C40H61O8P (700.4104)


   

2-[[(2S)-2-dodecanoyloxy-3-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2S)-2-dodecanoyloxy-3-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-7-enoate

[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-7-enoate

C39H73O8P (700.5043)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C37H65O10P (700.4315)


   

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-docos-13-enoate

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-docos-13-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-7-enoate

[(2R)-1-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-7-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-9-enoate

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-9-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-7-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-11-enoate

[(2R)-1-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-11-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

[(2R)-2-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-icos-11-enoate

[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-icos-11-enoate

C39H73O8P (700.5043)


   

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] octadec-17-enoate

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] octadec-17-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate

[(2R)-1-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate

C39H73O8P (700.5043)


   

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (13E,16E)-docosa-13,16-dienoate

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (13E,16E)-docosa-13,16-dienoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

[(2R)-1-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

[(2R)-1-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] icosanoate

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] icosanoate

C39H73O8P (700.5043)


   

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-11-enoate

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-11-enoate

C39H73O8P (700.5043)


   

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-13-enoate

[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (E)-octadec-13-enoate

C39H73O8P (700.5043)


   

[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate

[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate

C39H73O8P (700.5043)


   

2-[[(2S)-2-decanoyloxy-3-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2S)-2-decanoyloxy-3-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

[(2R)-1-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

[(2R)-1-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate

[(2R)-1-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate

C39H73O8P (700.5043)


   

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-11-enoate

[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-11-enoate

C39H73O8P (700.5043)


   

[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate

C39H73O8P (700.5043)


   

[(2R)-2-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

[(2R)-2-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropyl] octadecanoate

C39H73O8P (700.5043)


   

2-[[3-decanoyloxy-2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-decanoyloxy-2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

2-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

2-[[3-dodecanoyloxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-dodecanoyloxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

2-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-tetradecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-tetradecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

2-[[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

2-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H71NO8P+ (700.4917)


   

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphate

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphate

C39H73O8P (700.5043)


A 1-acyl-2-linoleoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as stearoyl (octadecanoyl).

   

PA(18:1(11Z)/18:1(11Z))

PA(18:1(11Z)/18:1(11Z))

C39H73O8P (700.5043)


   

1-(9Z,12Z-octadecadienoyl)-2-octadecanoyl-glycero-3-phosphate

1-(9Z,12Z-octadecadienoyl)-2-octadecanoyl-glycero-3-phosphate

C39H73O8P (700.5043)


   

1-tetradecanoyl-2-(13Z,16Z-docosadienoyl)-glycero-3-phosphate

1-tetradecanoyl-2-(13Z,16Z-docosadienoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

1-hexadecanoyl-2-(11Z,14Z-eicosadienoyl)-glycero-3-phosphate

1-hexadecanoyl-2-(11Z,14Z-eicosadienoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

1-(11Z-eicosenoyl)-2-(9Z-hexadecenoyl)-glycero-3-phosphate

1-(11Z-eicosenoyl)-2-(9Z-hexadecenoyl)-glycero-3-phosphate

C39H73O8P (700.5043)


   

1-(11Z,14Z-eicosadienoyl)-2-hexadecanoyl-glycero-3-phosphate

1-(11Z,14Z-eicosadienoyl)-2-hexadecanoyl-glycero-3-phosphate

C39H73O8P (700.5043)


   

1-(13Z,16Z-docosadienoyl)-2-tetradecanoyl-glycero-3-phosphate

1-(13Z,16Z-docosadienoyl)-2-tetradecanoyl-glycero-3-phosphate

C39H73O8P (700.5043)


   

PA(18:1(11Z)/18:1(9Z))

PA(18:1(11Z)/18:1(9Z))

C39H73O8P (700.5043)


   

1-oleoyl-2-(11Z)-octadecenoyl-sn-glycero-3-phosphate

1-oleoyl-2-(11Z)-octadecenoyl-sn-glycero-3-phosphate

C39H73O8P (700.5043)


A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as oleoyl and (11Z)-octadecenoyl respectively.

   

1,2-bis(octadec-9-enoyl)phosphatidic acid

1,2-bis(octadec-9-enoyl)phosphatidic acid

C39H73O8P (700.5043)


A phosphatidic acid (36:2) in which both acyl groups are specified as octadec-9-enoyl.

   

1-Oleoyl-2-stearoyl-sn-glycero-3-phosphate(2-)

1-Oleoyl-2-stearoyl-sn-glycero-3-phosphate(2-)

C39H73O8P (700.5043)


A 1-acyl-2-octadecanoyl-sn-glycero-3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-oleoyl-2-stearoyl-sn-glycero-3-phosphate.

   

phosphatidic acid 36:2

phosphatidic acid 36:2

C39H73O8P (700.5043)


A phosphatidic acid in which the two acyl groups contain a total of 36 carbons and 2 double bonds.

   

phosphatidylserine 30:3(1-)

phosphatidylserine 30:3(1-)

C36H63NO10P (700.4189)


A 3-sn-phosphatidyl-L-serine(1-) in which the acyl groups at C-1 and C-2 contain 30 carbons in total and 3 double bonds.

   

1-Stearoyl-2-oleoyl-sn-glycero-3-phosphate(2-)

1-Stearoyl-2-oleoyl-sn-glycero-3-phosphate(2-)

C39H73O8P (700.5043)


A 1,2-diacyl-sn-glycerol 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-stearoyl-2-oleoyl-sn-glycero-3-phosphate.

   

1,2-dioleoyl-sn-glycerol-3-phosphate

1,2-dioleoyl-sn-glycerol-3-phosphate

C39H73O8P (700.5043)


A 1-acyl-2-oleoyl-sn-glycerol-3-phosphate(2-) in which the 1-acyl group is also oleoyl.

   

BisMePA(34:2)

BisMePA(16:1_18:1)

C39H73O8P (700.5043)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

PEt(34:2)

PEt(16:0_18:2)

C39H73O8P (700.5043)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

PMe(35:2)

PMe(17:1_18:1)

C39H73O8P (700.5043)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

MGDG O-32:8

MGDG O-32:8

C41H64O9 (700.455)


   
   
   
   

PA O-16:0/20:3;O

PA O-16:0/20:3;O

C39H73O8P (700.5043)


   

PA O-18:0/18:3;O

PA O-18:0/18:3;O

C39H73O8P (700.5043)


   
   

PA P-16:0/20:2;O

PA P-16:0/20:2;O

C39H73O8P (700.5043)


   

PA P-18:0/18:2;O

PA P-18:0/18:2;O

C39H73O8P (700.5043)


   

PA P-18:1/18:1;O

PA P-18:1/18:1;O

C39H73O8P (700.5043)


   

PA 14:0/20:4;O2

PA 14:0/20:4;O2

C37H65O10P (700.4315)


   

PA 14:1/20:3;O2

PA 14:1/20:3;O2

C37H65O10P (700.4315)


   

PA 22:0/13:3;O

PA 22:0/13:3;O

C38H69O9P (700.4679)


   

PA 22:1/12:3;O2

PA 22:1/12:3;O2

C37H65O10P (700.4315)


   

PA 22:2/12:2;O2

PA 22:2/12:2;O2

C37H65O10P (700.4315)


   
   
   
   
   
   
   
   
   
   
   
   

PG O-10:0/22:4

PG O-10:0/22:4

C38H69O9P (700.4679)


   

PG O-14:0/18:4

PG O-14:0/18:4

C38H69O9P (700.4679)


   

PG O-14:1/18:3

PG O-14:1/18:3

C38H69O9P (700.4679)


   
   
   

PG P-14:0/18:3

PG P-14:0/18:3

C38H69O9P (700.4679)


   

PG P-14:0/18:3 or PG O-14:1/18:3

PG P-14:0/18:3 or PG O-14:1/18:3

C38H69O9P (700.4679)


   

PG P-18:1/13:3;O

PG P-18:1/13:3;O

C37H65O10P (700.4315)


   
   

PG P-32:3 or PG O-32:4

PG P-32:3 or PG O-32:4

C38H69O9P (700.4679)


   
   
   
   
   
   
   
   

Ac-SVVVRT-NH2

Ac-SVVVRT-NH2

C30H56N10O9 (700.4232)


Ac-SVVVRT-NH2 is a PGC-1α modulator that modulates the activity of the human PGC-1α promoter (114\\%). Ac-SVVVRT-NH2 increases PGC-1α mRNA (125\\%) and accumulation of intracellular lipids (128\\%) in subcutaneous human adipocytes. Ac-SVVVRT-NH2 can be used in the research of diseases which is modulated by PGC-1α[1]. Ac-SVVVRT-NH2 is a PGC-1α modulator that modulates the activity of the human PGC-1α promoter (114\%). Ac-SVVVRT-NH2 increases PGC-1α mRNA (125\%) and accumulation of intracellular lipids (128\%) in subcutaneous human adipocytes. Ac-SVVVRT-NH2 can be used in the research of diseases which is modulated by PGC-1α[1].

   

6-[3,9-dihydroxy-2,6-dimethyl-8-(2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl)nona-4,6-dien-2-yl]-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

6-[3,9-dihydroxy-2,6-dimethyl-8-(2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl)nona-4,6-dien-2-yl]-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

C41H64O9 (700.455)


   

methyl (1r,2s,3s,8s,11s,15r,18s,21r,22s,23z,27s,28r)-2,3,28-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl (1r,2s,3s,8s,11s,15r,18s,21r,22s,23z,27s,28r)-2,3,28-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H64O9 (700.455)


   

2-[(3s)-5-ethyl-6-[(2s,3s)-6-[(4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-(1-hydroxybutyl)-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2,4-dihydroxy-3-methyloxan-2-yl]butanoic acid

2-[(3s)-5-ethyl-6-[(2s,3s)-6-[(4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-(1-hydroxybutyl)-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2,4-dihydroxy-3-methyloxan-2-yl]butanoic acid

C38H68O11 (700.4761)


   

methyl (1r,2s,3s,8s,11s,15r,18s,21s,22s,23e,27s,28s)-2,3,28-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl (1r,2s,3s,8s,11s,15r,18s,21s,22s,23e,27s,28s)-2,3,28-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H64O9 (700.455)


   

(2r)-2-[(2r,3s,4r,5s,6r)-5-ethyl-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxybutyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2,4-dihydroxy-3-methyloxan-2-yl]butanoic acid

(2r)-2-[(2r,3s,4r,5s,6r)-5-ethyl-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxybutyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2,4-dihydroxy-3-methyloxan-2-yl]butanoic acid

C38H68O11 (700.4761)


   

(2r,3s,8s,14s,19s)-8,19-dibutyl-3,14-dimethyl-2-{[(2s,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}tricyclo[18.2.2.2⁹,¹²]hexacosa-1(22),9,11,20,23,25-hexaene-10,21,24,26-tetrol

(2r,3s,8s,14s,19s)-8,19-dibutyl-3,14-dimethyl-2-{[(2s,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}tricyclo[18.2.2.2⁹,¹²]hexacosa-1(22),9,11,20,23,25-hexaene-10,21,24,26-tetrol

C41H64O9 (700.455)


   

(6e,18e)-2,10,15-trihydroxy-2,6,10,15,19,23-hexamethyl-14-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-6,18,22-trien-11-yl acetate

(6e,18e)-2,10,15-trihydroxy-2,6,10,15,19,23-hexamethyl-14-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-6,18,22-trien-11-yl acetate

C38H68O11 (700.4761)


   

2,10,15-trihydroxy-2,6,10,15,19,23-hexamethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-6,18,22-trien-11-yl acetate

2,10,15-trihydroxy-2,6,10,15,19,23-hexamethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-6,18,22-trien-11-yl acetate

C38H68O11 (700.4761)


   

methyl 2,3,28-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl 2,3,28-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H64O9 (700.455)


   

6-[(3r,4z,6z,8r)-3,9-dihydroxy-2,6-dimethyl-8-[(2s,4s,6e,8e,10z,12s)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

6-[(3r,4z,6z,8r)-3,9-dihydroxy-2,6-dimethyl-8-[(2s,4s,6e,8e,10z,12s)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

C41H64O9 (700.455)


   

methyl 2,4,27-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl 2,4,27-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H64O9 (700.455)


   

2-(5-ethyl-6-{6-[5'-ethyl-2'-hydroxy-5'-(1-hydroxybutyl)-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl}-2,4-dihydroxy-3-methyloxan-2-yl)butanoic acid

2-(5-ethyl-6-{6-[5'-ethyl-2'-hydroxy-5'-(1-hydroxybutyl)-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl}-2,4-dihydroxy-3-methyloxan-2-yl)butanoic acid

C38H68O11 (700.4761)


   

(6e,10s,11s,14s,15r,18e)-2,10,15-trihydroxy-2,6,10,15,19,23-hexamethyl-14-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-6,18,22-trien-11-yl acetate

(6e,10s,11s,14s,15r,18e)-2,10,15-trihydroxy-2,6,10,15,19,23-hexamethyl-14-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-6,18,22-trien-11-yl acetate

C38H68O11 (700.4761)


   

6-[(3r,4z,6e,8r)-3,9-dihydroxy-2,6-dimethyl-8-[(2r,4s,6e,8z,10e,12r)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4r,6r)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

6-[(3r,4z,6e,8r)-3,9-dihydroxy-2,6-dimethyl-8-[(2r,4s,6e,8z,10e,12r)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4r,6r)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

C41H64O9 (700.455)


   

[(1r,3s,3ar,5as,5bs,6s,7ar,9r,10r,11as,13ar,13br)-1,6,9,10-tetrakis(acetyloxy)-3-isopropyl-5a,8,8,11a,13a-pentamethyl-1h,2h,3h,4h,5h,5bh,6h,7h,7ah,9h,10h,11h,13h,13bh-cyclopenta[a]chrysen-3a-yl]methyl acetate

[(1r,3s,3ar,5as,5bs,6s,7ar,9r,10r,11as,13ar,13br)-1,6,9,10-tetrakis(acetyloxy)-3-isopropyl-5a,8,8,11a,13a-pentamethyl-1h,2h,3h,4h,5h,5bh,6h,7h,7ah,9h,10h,11h,13h,13bh-cyclopenta[a]chrysen-3a-yl]methyl acetate

C40H60O10 (700.4186)


   

3,7,11-trihydroxy-2,4,6,8,10,12,14,16,18,20-decamethyl-15-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}docosa-4,8,12-trienoic acid

3,7,11-trihydroxy-2,4,6,8,10,12,14,16,18,20-decamethyl-15-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}docosa-4,8,12-trienoic acid

C38H68O11 (700.4761)


   

methyl (1r,2s,4r,8r,11s,14r,18s,21s,22r,23e,27s,28r)-2,4,28-trihydroxy-11-isopropyl-2,6,14,18,24,28-hexamethyl-10,13,20-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-8-carboxylate

methyl (1r,2s,4r,8r,11s,14r,18s,21s,22r,23e,27s,28r)-2,4,28-trihydroxy-11-isopropyl-2,6,14,18,24,28-hexamethyl-10,13,20-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-8-carboxylate

C41H64O9 (700.455)


   

methyl (1r,2s,4r,8s,11s,15r,18s,21s,22s,23e,27r,28s)-2,4,27-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl (1r,2s,4r,8s,11s,15r,18s,21s,22s,23e,27r,28s)-2,4,27-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H64O9 (700.455)


   

6-[(3r,4z,6z,8r)-3,9-dihydroxy-2,6-dimethyl-8-[(2r,4s,6e,8z,10e,12r)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4r,6r)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

6-[(3r,4z,6z,8r)-3,9-dihydroxy-2,6-dimethyl-8-[(2r,4s,6e,8z,10e,12r)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4r,6r)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

C41H64O9 (700.455)


   

(1r,4s,6s,9z,13s,14s,17r)-17-{2-[(1r,4s,6s,9e,13s,14s,17s)-13,17-dihydroxy-4,9,13-trimethyl-16-oxo-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-17-yl]ethyl}-13-hydroxy-4,9,13,17-tetramethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-16-one

(1r,4s,6s,9z,13s,14s,17r)-17-{2-[(1r,4s,6s,9e,13s,14s,17s)-13,17-dihydroxy-4,9,13-trimethyl-16-oxo-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-17-yl]ethyl}-13-hydroxy-4,9,13,17-tetramethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-16-one

C41H64O9 (700.455)


   

(2s,3s)-2-[(2s)-2-{[(2s)-2-[(2s)-2-[(2s)-n,3-dimethyl-2-(n-methyl-1-phenylformamido)butanamido]-n,3-dimethylbutanamido]-1-hydroxy-3-methylbutylidene]amino}-n,3-dimethylbutanamido]-n,3-dimethylpentanimidic acid

(2s,3s)-2-[(2s)-2-{[(2s)-2-[(2s)-2-[(2s)-n,3-dimethyl-2-(n-methyl-1-phenylformamido)butanamido]-n,3-dimethylbutanamido]-1-hydroxy-3-methylbutylidene]amino}-n,3-dimethylbutanamido]-n,3-dimethylpentanimidic acid

C38H64N6O6 (700.4887)


   

methyl 2,4,28-trihydroxy-11-isopropyl-2,6,14,18,24,28-hexamethyl-10,13,20-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-8-carboxylate

methyl 2,4,28-trihydroxy-11-isopropyl-2,6,14,18,24,28-hexamethyl-10,13,20-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-8-carboxylate

C41H64O9 (700.455)


   

6-[(4e,6e)-3,9-dihydroxy-2,6-dimethyl-8-[(6e,8e,10e)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

6-[(4e,6e)-3,9-dihydroxy-2,6-dimethyl-8-[(6e,8e,10e)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

C41H64O9 (700.455)


   

6-[(4e,6e)-3,9-dihydroxy-2,6-dimethyl-8-[(6e,8e,10e)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

6-[(4e,6e)-3,9-dihydroxy-2,6-dimethyl-8-[(6e,8e,10e)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

C41H64O9 (700.455)


   

methyl (1r,2r,4r,8s,11s,15r,18s,21s,22s,23e,27r,28s)-2,4,27-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl (1r,2r,4r,8s,11s,15r,18s,21s,22s,23e,27r,28s)-2,4,27-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H64O9 (700.455)


   

6-[(4e,6e)-3,9-dihydroxy-2,6-dimethyl-8-[(6e,8e,10e)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

6-[(4e,6e)-3,9-dihydroxy-2,6-dimethyl-8-[(6e,8e,10e)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

C41H64O9 (700.455)


   

6-[(4e,6e)-3,9-dihydroxy-2,6-dimethyl-8-[(6e,8e,10e)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

6-[(4e,6e)-3,9-dihydroxy-2,6-dimethyl-8-[(6e,8e,10e)-2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl]nona-4,6-dien-2-yl]-3-[(2s,3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

C41H64O9 (700.455)


   

2-{2-[(2-{2-[n,3-dimethyl-2-(n-methyl-1-phenylformamido)butanamido]-n,3-dimethylbutanamido}-1-hydroxy-3-methylbutylidene)amino]-n,3-dimethylbutanamido}-n,3-dimethylpentanimidic acid

2-{2-[(2-{2-[n,3-dimethyl-2-(n-methyl-1-phenylformamido)butanamido]-n,3-dimethylbutanamido}-1-hydroxy-3-methylbutylidene)amino]-n,3-dimethylbutanamido}-n,3-dimethylpentanimidic acid

C38H64N6O6 (700.4887)


   

6-[3,9-dihydroxy-2,6-dimethyl-8-(2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl)nona-4,6-dien-2-yl]-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

6-[3,9-dihydroxy-2,6-dimethyl-8-(2,4,6,10,12-pentamethyltetradeca-6,8,10-trien-1-yl)nona-4,6-dien-2-yl]-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

C41H64O9 (700.455)


   

methyl (1s,2s,4r,8s,11s,15r,18s,21s,22s,23e,27s,28s)-2,4,27-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl (1s,2s,4r,8s,11s,15r,18s,21s,22s,23e,27s,28s)-2,4,27-trihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H64O9 (700.455)


   

(2r,3s,4e,6s,7s,8e,10s,11s,12e,14s,15r,16s,18s,20s)-3,7,11-trihydroxy-2,4,6,8,10,12,14,16,18,20-decamethyl-15-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}docosa-4,8,12-trienoic acid

(2r,3s,4e,6s,7s,8e,10s,11s,12e,14s,15r,16s,18s,20s)-3,7,11-trihydroxy-2,4,6,8,10,12,14,16,18,20-decamethyl-15-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}docosa-4,8,12-trienoic acid

C38H68O11 (700.4761)